Evolus has filed a material event with the SEC, suggesting a significant corporate or commercial action affecting Jeuveau (prabotulinumtoxinA-xvfs), the company's neuromodulator competitor to Botox. While the specific details remain under wraps pending full disclosure, the timing and cadence of filings point to pricing adjustments, loyalty program restructuring, or distribution changes within the Evolus Rewards ecosystem.